Prospective, Multicenter, Randomized, Double Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Moxifloxacin 400 mg OD for 7 Days Versus a Standard Antibiotic Therapy for 10 Days in the Treatment of Acute Bacterial Rhino Sinusitis.

Trial Profile

Prospective, Multicenter, Randomized, Double Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Moxifloxacin 400 mg OD for 7 Days Versus a Standard Antibiotic Therapy for 10 Days in the Treatment of Acute Bacterial Rhino Sinusitis.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Moxifloxacin (Primary) ; Amoxicillin/clavulanic acid
  • Indications Acute sinusitis; Bacterial infections
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 15 Sep 2010 Results presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • 14 Apr 2009 Actual patient numbers changed from 594 to 293 as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top